-- Grand View Research puts the global antibody production market at USD 15.44 billion for 2024, with projections of USD 39.80 billion by 2033, an 11.2 percent compound annual growth rate tied directly to the expansion of biologic drug pipelines and the rising volume of pre-clinical validation work being outsourced to specialist CROs.
Biointron Biological Inc., a contract research organization based in Cambridge, Massachusetts, has launched Small-Scale Antibody Expression Packages under the RushMab™ brand, compressing antibody delivery timelines to as few as 10 days for purified, quality-controlled material.
Pharma and biotech companies are outsourcing more pre-clinical work than ever before. The antibody contract manufacturing segment alone represented USD 34.72 billion in addressable opportunity as of 2026, per a market report published in April of that year via GlobeNewswire.
Speed is now the primary variable. When expression turnaround runs long, candidate screening cycles slip with it, sometimes by weeks, and for research-stage companies working under tight capital constraints, those delays carry real cost. The shift has made fast, small-batch CRO capability a procurement priority rather than a convenience.
For more information, visit https://www.biointron.com/antibody-production/rushmab-small-scale-expression-packages.html
Recombinant antibody expression converts a sequence file into a functional protein a research team can actually use. Biointron's RushMab™ line covers that process at four delivery speeds. Teams that only need plasmid material can get 100 micrograms of transfection-grade expression plasmids from the RushMab™-Gene package in four days.
RushMab™ Super adds purification and delivers antibody with titer detection in eight. Both Mini and Standard packages hit the 10-day mark with full purification: the Mini at a minimum of 100 micrograms, the Standard at over 1 milligram, with endotoxin testing below 1 EU/mg and SDS-PAGE plus SEC-HPLC verification on both. IgG, Fab, VHH, and ScFv formats are all supported, covering the structural range most common in early biologic research. Service details are on Biointron's Small-Scale Antibody Expression Packages page.
Speed-to-delivery has become the main competitive axis in small-scale antibody expression. GenScript Biotech Corporation, listed on the Hong Kong Stock Exchange, runs a TurboCHO™ transient expression platform that publishes five-business-day turnaround for select configurations.
Sino Biological cites a 10-day gene-to-antibody standard across its high-throughput recombinant service. Biointron competes at that same benchmark with the added breadth of IgG, Fab, VHH, and ScFv support in one service menu. ISO 9001:2015 certification and membership in MassBio – the Massachusetts life sciences industry association – round out the compliance profile that pharmaceutical procurement teams typically require.
"As biologic pipelines grow and AI-driven candidate generation accelerates, the wet-lab expression step has become the rate-limiting factor in early research programs," said Mia Deng of Biointron Biological Inc. She noted that RushMab™ was built to keep pace with how fast modern discovery workflows now move. "A 10-day turnaround for a fully purified, endotoxin-tested antibody removes a friction point that used to cost teams weeks between candidate iterations."
Biointron was founded in 2012. Since then it has delivered recombinant antibody services to more than 2,500 biotech and pharmaceutical organizations spanning more than 20 countries. In 2025, Scientist.com recognized the company with its Supplier Performance Recognition Award for drug discovery research services.
Cambridge, Massachusetts, puts Biointron inside one of North America's most concentrated corridors for biologic research, academic medical centers, pharmaceutical research units, and venture-backed startups, all operating within close proximity and generating consistent demand for fast, reliable CRO output. The full range of Antibody Expression Packages is available on the company's website.
About Biointron Biological Inc.
Biointron Biological Inc. is a Cambridge, Massachusetts-based contract research organization specializing in antibody discovery, antibody production, stable cell line development, and protein expression services for biotech and pharmaceutical clients worldwide. Founded in 2012 and ISO 9001:2015 certified, Biointron has served more than 2,500 organizations across more than 20 countries.
Contact Info:
Name: Mia Deng
Email: Send Email
Organization: Biointron Biological Inc.
Address: 20 University Road, Suite 500, Cambridge, MA 02138
Phone: +1 (732) 790-8340
Website: https://www.biointron.com/
Release ID: 89193298
Google
RSS